In one paragraphArticle in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
12 authors.
Caitlin S DecinaDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.ORCID 0009-0003-1106-0519 Nicole M WarringtonInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-4195-775X Robin N BeaumontDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.ORCID 0000-0003-0750-8248 Beilei BianInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-4849-1094 Caroline Brito NunesInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-2654-1679 Geng WangInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-2478-2919 David SquireSchool of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, 3052, Australia.ORCID 0000-0001-6738-8271 Damjan VukcevicSchool of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, 3052, Australia.ORCID 0000-0001-7780-9586 Stephen LeslieSchool of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, 3052, Australia.ORCID 0000-0003-3511-3470 Rachel M FreathyDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.ORCID 0000-0003-4152-2238 David M EvansInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-0663-4621 Funding
Zosuquidar trihydrochloride for acute myeloid leukemia &refractory anemiaM01RR000080 · NCRR · UNIVERSITY HOSPITALS OF CLEVELAND · PI DEARBORN, DORR GELLATLY · 1985 to 2007
$22.2MWOMEN'S INTERAGENCY HIV STUDY (WIHS) INTENSIVE PHARMACOKINETICS STUDYM01RR000048 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ARICETA, GEMA · 1985 to 2007
$21.1MHyperglycemia and Adverse Pregnancy Outcome (HAPO)R01HD034243 · NICHD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI METZGER, BOYD E · 1999 to 2010
$16.2MHAPO: DATA COORDINATING CENTERR01HD034242 · NICHD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DYER, ALAN R · 1999 to 2007
$3.0MIntegrating genomic studies of gestational duration and birth weight to understand maternal and fetal causes of adverse pregnancy outcomes and links with later diseasesR01HD101669 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI FREATHY, RACHEL, JACOBSSON, BO · 2021 to 2024
$2.1MNCRR NIH HHS M01 RR000048NCRR NIH HHS M01 RR000080NICHD NIH HHS R01 HD034242NICHD NIH HHS R01 HD034243NICHD NIH HHS R01 HD101669Wellcome Trust
6 · The paper itselfAbstract
Human birth weight is under stabilizing selection, seeking balance between extremes of high and low, thereby reducing fetal and maternal perinatal mortality risk. Certain combinations of maternal killer immunoglobulin-like receptor (
Identifiers
PMID40297441
PMCPMC12036411
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390